Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fulcrum Therapeutics's enterprise value is $-29.74 Mil.
Fulcrum Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-85.40 Mil. Therefore, Fulcrum Therapeutics's EV-to-EBITDA for today is 0.35.
The historical rank and industry rank for Fulcrum Therapeutics's EV-to-EBITDA or its related term are showing as below:
FULC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -66.44 Med: -2.66 Max: 6.9
Current: 0.35
During the past 9 years, the highest EV-to-EBITDA of Fulcrum Therapeutics was 6.90. The lowest was -66.44. And the median was -2.66.
FULC's EV-to-EBITDA is ranked better than 88.44% of 398
companies
in the Biotechnology industry
Industry Median: 13.395
vs FULC: 0.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fulcrum Therapeutics's PE Ratio (TTM) for today is calculated as:
Fulcrum Therapeutics's share price for today is $3.725.
Fulcrum Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Fulcrum Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fulcrum Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulcrum Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fulcrum Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fulcrum Therapeutics's EV-to-EBITDA falls into.
Fulcrum Therapeutics's current Enterprise Value is $-29.74 Mil.
Fulcrum Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-85.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulcrum Therapeutics (FULC) has a EV-to-EBITDA of 0.35 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fulcrum Therapeutics. According to the industry distribution chart, Fulcrum Therapeutics ranks #46 out of 398 companies in the Biotechnology industry, placing it in the top 11.6%.
Is Fulcrum Therapeutics' EV-to-EBITDA too high?
Fulcrum Therapeutics' current EV-to-EBITDA is 0.35. The Biotechnology industry median EV-to-EBITDA is 13.40. Fulcrum Therapeutics' value of 0.35 is 97.4% below this industry median. Based on the distribution chart, Fulcrum Therapeutics ranks #46 out of 398 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fulcrum Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fulcrum Therapeutics' EV-to-EBITDA compare to AGEN and IRD?
According to the Biotechnology industry distribution chart, Fulcrum Therapeutics ranks #46 out of 398 companies for EV-to-EBITDA. This places Fulcrum Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.40. Fulcrum Therapeutics' value of 0.35 is 97.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.40, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fulcrum Therapeutics's current EV-to-EBITDA of 0.35 is 97.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fulcrum Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulcrum Therapeutics's current EV-to-EBITDA is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulcrum Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fulcrum Therapeutics (FULC) is currently considered Possible Value Trap. The stock's GF Value™ is $32.03, compared to a current price of $3.73 — trading 88.4% below its estimated fair value. The current EV-to-EBITDA is 0.35 and 97.4% below the Biotechnology industry median of 13.40. Fulcrum Therapeutics' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Fulcrum Therapeutics (FULC), the current EV-to-EBITDA is 0.35 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulcrum Therapeutics (FULC) Overvalued in 2026?
Based on GuruFocus' analysis, Fulcrum Therapeutics stock appears to be undervalued.
The current stock price of $3.73 is trading 88.4% below its estimated GF Value™ of $32.03.
GuruFocus considers Fulcrum Therapeutics to be Possible Value Trap.
Key valuation signals for FULC:
EV-to-EBITDA: 0.35
GF Value™: $32.03 vs. price of $3.73 (88.4% below fair value)
Industry Position: 97.4% below the Biotechnology median (#46 of 398)
No single metric tells the full story. See the FULC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
44GF Score
Get the complete analysis for FULC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FULC has been successfully added to your 
